Clinical Trial

Prognostic and Predictive Role of Intrinsic Molecular Subtypes in BRCA-associated Breast Cancer

Study acronym: PAMBRACA
Recruiting
View on ClinicalTrials.gov →
Summary
This study is an observational study being carried out in several hospitals. No extra tests or procedures are required beyond those already part of normal medical care. The study is sponsored by the University of Modena and Reggio Emilia and aims to include about 100 patients. The main goal of the study is to better understand the different biological types of breast cancer in patients who have hormone receptor-positive (HR-positive), HER2-negative breast cancer related to BRCA gene mutations. In particular, the study will explore whether these cancers tend to belong to molecular types that may respond less to endocrine or CDK4/6 inhibitor therapy. The study also compares cancers linked to BRCA1 and BRCA2 mutations and investigates whether the different biological types are associated with differences in disease outcomes and response to treatment.
Trial Details
NCT Number NCT07617025
Lead Sponsor Angela Toss
Conditions Breast Cancer
Enrollment 100 participants
Start Date 2024-09-05
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-01